2025年欧洲肿瘤内科学会乳腺癌年会（2025 ESMO BREAST CANCER Annual Congress）将于5月15日至17日（Central European Summer Time，CEST）在德国慕尼黑国际会议中心举行。大会将汇聚世界各地的顶尖专家，共同探讨和交流最新的研究成果和临床进展。【肿瘤资讯】整理了口头报告研究题目信息，提前为您揭晓大会的精彩内容。
优选论文专场1
Proffered Paper session 1
专场时间：5月14日 16:30-18:00
专场地点：Room 14
专场主席：Erika P. Hamilton (Nashville, United States of America)，Masakazu Toi (Bunkyo-ku, Japan)
摘要号：297O
中文标题：Imlunestrant联合或不联合阿贝西利治疗晚期乳腺癌：EMBER-3试验中CDK4/6抑制剂（CDK4/6i）经治患者的亚组分析
英文标题：Imlunestrant (Imlu) with or without Abemaciclib (Abema) in Advanced Breast Cancer (ABC): a Subgroup Analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated Patients (pts) from EMBER-3
讲者：Cristina Saura Manich (Barcelona, Spain)
摘要号：1O
中文标题：PADA-1试验中HR+/HER2-转移性乳腺癌患者接受AI和哌柏西利治疗后血液ESR1突变的动力学及决定因素
英文标题：Kinetics and determinants of blood ESR1 mutation under AI and palbociclib in HR+/HER2- metastatic breast cancer patients in the PADA-1 trial.
讲者：François Clément Bidard (Paris, France)
摘要号：415O
中文标题：POSITIVE试验中中断辅助内分泌治疗以尝试怀孕的乳腺癌患者生育力的预测因素
英文标题：Predictive Factors of Fertility in Patients with Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy in the POSITIVE trial.
讲者：Fedro A. Peccatori (Milan, Italy)
摘要号：416O
中文标题：年轻 BRCA 突变携带者妊娠期间诊断乳腺癌（PrBC）后再次妊娠的安全性
英文标题：Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers
讲者：Marta Perachino (Barcelona, Spain)
优选论文专场2
Proffered Paper session 2
专场时间：5月15日 14：00-15:30
专场地点：Room 14
专场主席：Masakazu Toi (Bunkyo-ku, Japan)，Nicholas Turner (London, United Kingdom)
摘要号：2O
中文标题：将肿瘤浸润淋巴细胞及淋巴结状态整合用于接受新辅助治疗后达到病理完全缓解的TNBC患者的风险分层
英文标题：Integrating Tumor Infiltrating Lymphocytes and Nodal Status for Risk Stratification in Patients (pts) with Triple-Negative Breast Cancer (TNBC) and Pathological Complete Response (pCR) after Neoadjuvant Treatment (NAT)
讲者：Davide Massa (Padova, Italy)
摘要号：189O
中文标题：瑞波西利 + 内分泌治疗 vs 标准化疗用于中危HR+/HER2- 早期乳腺癌：Ⅲ期WSG ADAPTcycle 试验新辅助队列结果
英文标题：Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle - trial
讲者：Nadia Harbeck (Munich, Germany)
摘要号：190O
中文标题：OPTIMA prelim（利用多参数分析优化早期乳腺癌个体化治疗）可行性研究的临床结局
英文标题：Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study.
讲者：Robert C. Stein (London, United Kingdom)
简短口头报告专场1
Mini Oral session 1
专场时间：5月15日 8:30-10:00
专场地点：Room 14
专场主席：David Cescon (Toronto, ON, Canada)，Kevin Punie (Antwerp, Belgium)，Charlotte E. Coles (Cambridge, United Kingdom)
摘要号：298MO
中文标题：Emiltatug Ledadotin（Emi-Le，一种 B7-H4 靶向抗体偶联药物）在接受过至少一种拓扑异构酶 - 1 抑制剂（Topo-1 ADC）的TNBC患者中的临床活性
Clinical Activity of Emiltatug Ledadotin (Emi-Le), a B7-H4-Directed ADC, in Patients with TNBC who Received at Least One Prior Topoisomerase-1 Inhibitor (Topo-1) ADC
讲者：Erika P. Hamilton (Nashville, United States of America)
摘要号：299MO
中文标题：DESTINY-Breast06（DB-06）试验按医生选择化疗（TPC）的事后分析：T-DXd vs TPC 在HR+、HER2 低表达或超低表达转移性乳腺癌（mBC）中的疗效和安全性
英文标题：DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor-positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
讲者：Carlos H. Barrios (Porto Alegre, Brazil)
摘要号：300MO
中文标题：Puxitatug samrotecan（P-Sam，AZD8205）用于 HR+/HER2- 乳腺癌患者的首例人体 1/2a 期剂量递增和扩展研究
英文标题：Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2- breast cancer (BC): a first-in-human Phase 1/2a dose escalation and expansion study
讲者：Richard D. Baird (Cambridge, United Kingdom)
摘要号：152MO
中文标题：HER2阳性乳腺癌患者术后放疗分析：基于辅助拉帕替尼和/或曲妥珠单抗治疗优化试验（ALTTO）[BIG 2-06/NCCTG N063D (Alliance)]
英文标题：Post-mastectomy radiation therapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2) -positive breast cancer: analysis of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) Trial [BIG 2-06/NCCTG N063D (Alliance)]
讲者：Maria Carmen De Santis (Milan, Italy)
摘要号：153MO
中文标题：高危乳腺癌患者 1 周 vs 2 周大分割辅助放疗（HYPART）：一项非劣效性、开放标签、III 期随机试验
英文标题：HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART):A non-inferiority, open-label, phase III randomized trial.
讲者：Budhi S. Yadav (Chandigarh, India)
摘要号：267MO
中文标题：乳腺剪切波弹性成像深度学习模型改善乳腺癌诊断（INSPiRED 006）：一项国际多中心分析
英文标题：A Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis
讲者：Lie Cai (Heidelberg, Germany)
摘要号：301MO
中文标题：tremelimumab和度伐利尤单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期 HER2 阳性乳腺癌的初步疗效结果：BCT1703 DIAmOND 试验
英文标题：Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND
讲者：Sherene Loi (Melbourne, Australia)
摘要号：191MO
中文标题：标准新辅助化疗后残留乳腺癌患者中 Talimogene Laherparepvec（T-VEC）联合阿替利珠单抗治疗：SOLTI-PROMETEO 研究生存结果
英文标题：Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab (atezo) in patients (pts) with residual breast cancer (BC) after standard neoadjuvant chemotherapy (NAC): Survival results of the SOLTI-PROMETEO study
讲者：Tomás Pascual (Barcelona, Spain)
简短口头报告专场2
Mini Oral session 2
专场时间：5月16日 08:20 - 10:10
专场地点：Room 1
专场主席：Cristina Saura Manich (Barcelona, Spain)，François Clément Bidard (Paris, France)，Hope S. Rugo (San Francisco, CA, United States of America)
摘要号：192MO
中文标题：ROSALINE 试验主要终点：内分泌治疗联合恩曲替尼用于浸润性小叶乳腺癌（ILBC）的 II 期新辅助研究
英文标题：Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC)
讲者：Soraia Lobo-Martins (Brussels, Belgium)
摘要号：3MO
中文标题：MATADOR 试验中免疫组化生物标志物预测早期乳腺癌患者辅助化疗反应
英文标题：Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial
讲者：Mark Opdam (Amsterdam, Netherlands)
摘要号：4MO
中文标题：CDKPredX的开发和验证：ER+/HER2-乳腺癌中新辅助内分泌治疗联合CDK4/6抑制剂对比化疗的疗效预测工具——随机II期PREDIX Luminal B试验相关分析
英文标题：Development and validation of CDKPredX, a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2- breast cancer: Correlative analysis of the randomized phase 2 PREDIX Luminal B trial
讲者：Theodoros Foukakis (Stockholm, Sweden)
摘要号：417MO
中文标题：识别有害体重变化及其对乳腺癌结局的影响：来自护士健康研究的见解
英文标题：Identifying harmful weight changes and their impact on breast cancer outcomes: insights from the Nurses' Health Studies
讲者：Sixten Harborg (Aarhus, Denmark)
摘要号：302MO
中文标题：iza-bren（BL-B01D1，一种 EGFR x HER3 双特异性抗体偶联药物）用于局部晚期或转移性乳腺癌患者的 I 期研究
英文标题：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Breast Cancer (BC)
讲者：Yiqun Du (Shanghai, China)
摘要号：303MO
中文标题：Zanidatamab联合化疗治疗 HER2 表达转移性乳腺癌患者：I 期试验最终结果
英文标题：Zanidatamab (Zani) + Chemotherapy (Chemo) for Patients (Pts) With HER2-Expressing Metastatic Breast Cancer (mBC): Final Results of a Phase 1 Trial
讲者：Erika P. Hamilton (Nashville, United States of America)
摘要号：304MO
中文标题：图卡替尼联合曲妥珠单抗治疗既往接受过治疗的 HER2 突变转移性乳腺癌：II 期篮子研究（SGNTUC-019）最终分析
英文标题：Tucatinib and trastuzumab for previously treated HER2-mut MBC: final analysis of a phase 2 basket study (SGNTUC-019)
讲者：Alicia Okines (London, United Kingdom)
摘要号：305MO
中文标题：TDM-1 联合哌柏西利治疗转移性 HER2 阳性乳腺癌的 II 期试验
英文标题：Phase II trial of TDM-1 and Palbociclib in Metastatic HER2 positive Breast Cancer
讲者：Pavani Chalasani (Washington, DC, United States of America)
摘要号：5MO
中文标题：治疗前循环肿瘤DNA（ctDNA）预测I-SPY 2试验中高风险早期乳腺癌患者的转移性复发
英文标题：Pretreatment Circulating Tumor (ct)DNA Predicts Metastatic Recurrence in Patients (pts) With High-Risk Early Breast Cancer (eBC) Enrolled in the I-SPY 2 Trial
讲者：Mark Magbanua (San Francisco, CA, United States of America)
摘要号：6MO
中文标题：基线ctDNA和甲基化状态作为阿贝西利联合氟维司群治疗晚期乳腺癌的III期postMONARCH试验疗效预测指标
英文标题：Baseline ctDNA and methylation status as predictors of treatment benefit in the Phase 3 postMONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients
Seth Wander (Boston, MA, United States of America)
摘要号：193MO
中文标题：FDG-PET/CT和MRI对早期三阴性乳腺癌（eTNBC）新辅助免疫治疗（IO）反应的预测价值：II期BELLINI试验探索性分析
英文标题：Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy (IO) response in early-stage triple negative breast cancer (eTNBC): exploratory analysis of the phase 2 BELLINI trial
讲者：Gil Awada (Jette, Belgium)
5月14日会议日程
5月15日会议日程
5月16日会议日程
5月17日会议日程
https://cslide.ctimeetingtech.com/coasis_21219/attendee/confcal/session/calendar
排版编辑：肿瘤资讯-张薪媛
本文专供医学专业人士参考，未经著作人许可，不可出版发行。同时，欢迎个人转发分享，其他任何媒体、网站如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明“转自：良医汇-肿瘤医生APP”。
苏公网安备32059002004080号
